Pharmacokinetics and leukocyte responses of recombinant human interleukin-10

Pharmaceutical Research

Volumn 15, Issue 12, 1998, Pages 1895-1901

  Radwanski, Elaine ^a   Chakraborty, Abhijit ^b   Van Wart, Scott ^a   Huhn, Richard D ^b   Cutler, David L ^a   Affrime, Melton B ^a   Jusko, William J ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cytokines; IL 10; Immunosuppression; Pharmacokinetics; Protein

Indexed keywords

INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CROSS-OVER STUDIES; HUMANS; IMMUNOSUPPRESSION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1; INTERLEUKIN-10; LEUKOCYTES; MALE; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032410915     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011918425629     Document Type: Article

References (26)

1. D. F. Fiorentino, M. W. Bond, and T. R. Mosmann. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081-2095 (1989).
2. J. E. de Vries. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann. Med. 27:537-541 (1995).
3. K. W. Moore, A. O'Garra, R. de W. Malefyt, P. Vieira, and T. R. Mosmann. Interleukin-10. Annu. Rev. Immunol. 11:165-190 (1993).
4. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra, IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822 (1991).
5. T. Kasama, R. M. Strieter, N. W. Lukacs, M. D. Burdick, and S. L. Kunkel. Regulation of neutrophil-derived chemokine expression by IL-10. J. Immunol. 152:3559-3569 (1994).
6. K. Taga, H. Mostowski, and G. Tosato. Human interleukin-10 can directly inhibit T-cell growth. Blood. 81:2964-2971 (1993).
7. M. Howard, T. Muchamuel, S. Andrade, and S. Menon. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205-1208 (1993).
8. A. G. D. Bean, R. A. Freiberg, S. Andrade, S. Menon, and A. Zlotnik. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect. Immun. 61:4937-4939 (1993).
9. O. Rott, B. Fleischer, and E. Cash. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1434-1440 (1994).
10. R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75:263-274 (1993).
11. P. D. Katsikis, C-Q. Chu, F. M. Brennan, R. N. Maini, and M. Feldmann. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med 179:1517-1527 (1994).
12. R. D. Huhn, E. Radwanski, S. M. O'Connell, M. G. Sturgill, L. Clarke, R. P. Cody, M. B. Affrime, and D. L. Cutler. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 87:699-705 (1996).
13. S. Schreiber, T. Heinig, H-G. Theile, and A. Raedler. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:1434-1444 (1995).
14. R. D. Huhn, E. Radwanski, J. Gallo, M. B. Affrime, R. Sabo, G. Gonyo, A. Monge, and D. L. Cutler. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin. Pharmacol. Ther. 62:171-180 (1997).
15. A. Takagi, H. Masuda, Y. Takakura, and M. Hashida. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmaco. Exp. Ther. 275:537-543 (1995).
16. N. Stute, W. L. Furman, M. Schell, and W. E. Evans. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J. Pharm. Sci. 84:824-828 (1995).
17. A. Supersaxo, W. R Hein, and H. Steffen. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7:167-169 (1990).
18. H. Cheng and W. J. Jusko. The area function method for assessing the drug absorption rate in linear systems with zero-order input. Pharm. Res. 6:133-139 (1989).
19. G. M. Ferron, M. Rochi, W. J. Jusko, and J.-M. Schulman. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36:874-883 (1996).
20. T. H. Adair and A. C. Guyton. Experimental Biology of the Lymphatic Circulation, Elsevier Science Publishers, 1985, pp. 1-44.
21. C. A. Gloff and R. J. Wills. Pharmacokinetics and Metabolism of Therapeutic Cytokines. In B. L. Ferraiolo et al. (eds.), Protein Pharmacokinetics and Metabolism, Plenum Press, New York, 1992, pp. 127-150.
22. J. M. Trang. Pharmacokinetics and Metabolism of Therapeutic and Diagnostic Antibodies. In B. L. Ferraiolo BL et al. (eds.), Protein Pharmacokinetics and Metabolism, Plenum Press, New York, 1992, pp. 223-271.
23. S. J. H. Van Deventer, C. O. Elson, and R. N. Fedorak. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 113:383-389 (1997).
24. P. Wang, P. Wu, M. I. Siegel, R. W. Egan, and M. M. Billah. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J. Immunol. 153:811-816 (1994).
25. J. V. S. Gobburu and W. J. Jusko. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv. Drug Deliv. Rev. 33:221-233 (1998).
26. B. D. Kahan, N. Tejpal, S Gibbons-Stubbers, M. Wang, S. Stepkowski, and T-C Chow. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and its triple combinations. Transplantation 55:894-900.